Pre-eclampsia and fetal growth restriction arise from disorders of placental development and
have some shared mechanistic features. Initiation is often rooted in the maldevelopment of a …

In the past two decades, several molecular targeted inhibitors have been developed and
evaluated clinically to improve the survival of patients with cancer. Molecular targeted …

Alternative splicing allows for the expression of multiple RNA and protein isoforms from one
gene, making it a major contributor to transcriptome and proteome diversification in …

Preeclampsia (PE) is a serious pregnancy complication, affecting about 5–7% of
pregnancies worldwide and is characterized by hypertension and damage to multiple …

Preeclampsia is a clinical syndrome defined as the new onset of hypertension and
proteinuria during the second half of pregnancy. 1 It afflicts 3% to 5% of pregnancies and is …

Preeclampsia, a syndrome affecting 5% of pregnancies, causes substantial maternal and
fetal morbidity and mortality. The pathophysiology of preeclampsia remains largely …

Biology of Vascular Endothelial Growth Factor | Endocrine Reviews | Oxford Academic Skip to
Main Content Advertisement Oxford Academic Journals Books Search Menu Information …

Vascular endothelial growth factor (VEGF) is a highly specific mitogen for vascular
endothelial cells. Five VEGF isoforms are generated as a result of alternative splicing from a …

Vascular endothelial growth factor (VEGF) is a well-known angiogenic factor that plays a
critical role in various physiological and pathological processes. VEGF also contributes to …

Vascular endothelial growth factor A (VEGF-A), the founding member of the vascular
permeability factor (VPF)/VEGF family of proteins, is an important angiogenic cytokine with …